CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).

Authors

Institutions

Publication Details

Journal
Cardiovascular Diabetology
Published
2025-05-02
DOI
https://doi.org/10.1186/s12933-025-02700-0
Citations
11
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
14.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Tatjana Milenković, Oliver Schnell, Nikolaus Marx, Helena W. Rodbard et al.
11 citations
Cardiovascular Diabetology
Diabetes Treatment and Management
14.24
article

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Tatjana Milenković, Oliver Schnell, Nikolaus Marx, Helena W. Rodbard, Barbara McGowan, Colin Mark Dayan, Othmar Moser, C Wendy Spearman, Per‐Henrik Groop, Alin Stirban, Hiddo J.L. Heerspink, Michel Jadoul, Xavier Cos, Dipesh Patel, Linong Ji, Naresh Kanumilli, Katharine Barnard‐Kelly, Ulf Landmesser, Lars Rydén, Elke Schäeffner, Antonio Ceriello, Thomas Först, Sofia Macieira, Tadej Battelino, Mahmoud Ibrahim, Mikhail Kosiborod, Chantal Mathieu, Beatriz Fernández‐Fernández, Jaime P. Almandoz, Νικόλαος Παπάνας, Francesco Giorgino, Paola Fioretto, Pınar Topsever, Sarah Jarvis, Lisa Anderson, Andreas F. H. Pfeiffer, Matthias Blüher, Igor Alexander Harsch, Boris Mankovsky, Frank Tacke, Dirk Müller‐Wieland, Dario Rahelić, Luca Busetto, Thomas Danne, Eberhard Standl, James R. Gavin, Stefano Del Prato, Luc Van Gaal, Lutz Heinemann, Doina Catrinou
article en
11 citations

Abstract

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).

Cardiovascular DiabetologyVol. 24(1)
Cliniques Universitaires Saint-Luc (BE), University Medical Center Groningen (NL), University of Helsinki (FI), University of Padua (IT), Baker Heart and Diabetes Institute (AU), Democritus University of Thrace (GR), Emory University (US), University of Ljubljana (SI), Ovidius University (RO), University of Cape Town (ZA), Scuola Superiore Sant'Anna (IT), St George's, University of London (GB), University of Groningen (NL), Medical University of Graz (AT), Peking University (CN), Helsinki University Hospital (FI), St George’s University Hospitals NHS Foundation Trust (GB), Ljubljana University Medical Centre (SI), Monash Medical Centre (AU), Southern Health NHS Foundation Trust (GB), Karolinska Institutet (SE), Helmholtz Zentrum München (DE), Manchester University NHS Foundation Trust (GB), MultiMedica (IT), Clinical Research Services (DE), Universitätsklinikum Aachen (DE), Peking University People's Hospital (CN), University Hospital Leipzig (DE), Hospital Universitario Fundación Jiménez Díaz (ES), Saint Luke's Hospital (US), Kent Hastanesi (TR), Park-Klinik Birkenwerder (DE), Asklepios (DE), Acıbadem Adana Hospital (TR), Folkhälsans Forskningscentrum (FI), University of Bayreuth (DE), University of Bari Aldo Moro (IT), Universidad Autónoma de Madrid (ES), Royal College of General Practitioners (GB), Charité - Universitätsmedizin Berlin (DE), Cardiff University (GB), Universidade Nova de Lisboa (PT), The University of Texas Southwestern Medical Center (US), RWTH Aachen University (DE), UCLouvain (BE)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Amarin Corporation, Insulet Corporation, MannKind Corporation, Cytokinetics, Dexcom, Pacira BioSciences, European Foundation for the Study of Diabetes, Daiichi-Sankyo, KU Leuven, Novo Nordisk, Astellas Pharma, Vifor Pharma, European Association for the Study of Diabetes, Servier, Roche Diabetes Care, Lilly Deutschland, Esperion Therapeutics, Wörwag Pharma, Merck Sharp and Dohme, Abbott Diabetes Care, Janssen Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 1%
Diabetes Treatment and Management
14.24
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.